The global allergy treatment market size reached USD 23.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 37.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.92% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 23.5 Billion |
Market Forecast in 2033
|
USD 37.0 Billion |
Market Growth Rate 2025-2033 | 4.92% |
Allergy treatment is a preventive medical cure for abnormal reactions to allergens, such as pollens, molds, animal dander, latex, insects, food, and medications. They trigger the release of histamine by the immune system that causes inflammation, rashes, itchiness, sneezing, runny nose, and red eyes. They can also cause various allergic conditions, including hay fever, asthma, rhinitis, and skin, food, and eye allergies. Allergy treatment includes anti-allergic drugs and immunotherapy that can be administered through oral, inhalers, and intranasal dosage forms. These treatment methods help reduce sensitivity and inflammation, decrease symptoms, and improve the quality of the patient’s life.
The increasing prevalence of various allergies across the globe is one of the primary factors driving the market growth. In line with this, favorable initiatives by governments and non-governmental organizations (NGOs) to sensitize the masses about the adversities of allergies and their appropriate treatment options are favoring the market growth. Furthermore, increasing demand for over-the-counter (OTC) drugs, coupled with a growing inclination toward self-medication among consumers, is acting as another growth-inducing factor. Additionally, the integration of artificial intelligence (AI), natural language processing (NLP), and machine learning (ML) for diagnosing allergic diseases, predicting patient outcomes for targeted interventions, analyzing immunological data, and improving care delivery is providing an impetus to market growth. Apart from this, the increasing demand for subcutaneous allergen-specific immunotherapy (SCIT) due to its effectiveness, safety, and ability to alter the immune system and provide systemic relief is creating a positive outlook for the market. Other factors, including significant healthcare expenditures, increasing geriatric population, extensive research and development (R&D) activities towards novel treatments, and rising incidences of asthma, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global allergy treatment market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, treatment, dosage form and distribution channel.
Breakup by Type:
Breakup by Treatment:
Breakup by Dosage Form:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Type, Treatment, Dosage Form, Distribution Channel, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global allergy treatment market was valued at USD 23.5 Billion in 2024.
We expect the global allergy treatment market to exhibit a CAGR of 4.92% during 2025-2033.
The rising prevalence of various allergic conditions, along with the increasing demand for allergy treatment methods to reduce sensitivity and inflammation, is primarily driving the global allergy treatment market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective allergy treatment procedures to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals or medical equipment.
Based on the type, the global allergy treatment market has been segmented into eye allergy, skin allergy, food allergy, asthma, rhinitis, and others. Among these, rhinitis currently holds the majority of the total market share.
Based on the treatment, the global allergy treatment market can be divided into anti-allergy drugs and immunotherapy. Currently, anti-allergy drugs exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global allergy treatment market include AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A., and Stallergenes Greer.